M. Martin-Facklam

发表

Physiologically Based Pharmacokinetic Modelling to Predict Single- and Multiple-Dose Human Pharmacokinetics of Bitopertin

N. Parrott, D. Hainzl, D. Alberati, 2013, Clinical Pharmacokinetics.

Quality markers of drug information on the Internet: an evaluation of sites about St. John's wort.

Falk Schubert, W. Haefeli, C. Gasse, 2002, The American journal of medicine.

Quality of drug information on the World Wide Web and strategies to improve pages with poor information quality. An intervention study on pages about sildenafil.

Michael Kostrzewa, Walter E Haefeli, Meret Martin-Facklam, 2003, British journal of clinical pharmacology.

Combining ‘Bottom-Up’ and ‘Top-Down’ Methods to Assess Ethnic Difference in Clearance: Bitopertin as an Example

P. Hu, N. Parrott, M. Martin-Facklam, 2015, Clinical Pharmacokinetics.

Managing the Impact of Immunogenicity in an Era of Immunotherapy: From Bench to Bedside.

T. Singer, K. Stubenrauch, Guido Steiner, 2021, Journal of pharmaceutical sciences.

Glycine Transporter Type 1 Occupancy by Bitopertin: a Positron Emission Tomography Study in Healthy Volunteers

James Robert Brašić, D. Wong, D. Umbricht, 2013, Neuropsychopharmacology.

Oral contraception does not alter single dose saquinavir pharmacokinetics in women.

W. Haefeli, T. Strowitzki, I. Walter‐Sack, 2004, British journal of clinical pharmacology.

Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.

C. Hofmann, M. Martin-Facklam, L. Banken, 2012, Clinical therapeutics.

Unexplained decrease of cyclosporin trough levels in a compliant renal transplant patient.

M. Martin-Facklam, M. Wiesel, A. Mandelbaum, 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Drug dosage in patients with renal failure optimized by immediate concurrent feedback

W. Haefeli, C. Surber, M. Martin-Facklam, 2001, Journal of General Internal Medicine.

Undeclared exposure to St. John's Wort in hospitalized patients.

W. Haefeli, I. Walter‐Sack, J. Burhenne, 2004, British journal of clinical pharmacology.

Inhibition of P-Glycoprotein by Newer Antidepressants

W. Haefeli, M. Martin-Facklam, J. Weiss, 2003, Journal of Pharmacology and Experimental Therapeutics.

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–&agr;-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial

J. Jankovic, J. Quinn, M. Grundman, 2018, JAMA neurology.

Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects

K. Bogman, N. Parrott, M. Martin-Facklam, 2017, Clinical pharmacology in drug development.

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.

M. Ostland, D. Umbricht, G. Garibaldi, 2014, JAMA psychiatry.

Simultaneous determination of hypericin and hyperforin in human plasma with liquid chromatography-tandem mass spectrometry.

W. Haefeli, G. Mikus, J. Burhenne, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Effects of Cytochrome P450 3A4 Inhibitors—Ketoconazole and Erythromycin—on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions

N. Parrott, D. Hainzl, C. Hofmann, 2016, Clinical Pharmacokinetics.

Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects

K. Bogman, N. Parrott, M. Martin-Facklam, 2017, Clinical pharmacology in drug development.

Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects

K. Nieforth, K. Bogman, K. Heinig, 2017, Xenobiotica; the fate of foreign compounds in biological systems.

Clinical Drug–Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib

K. Bogman, M. Martin-Facklam, P. N. Morcos, 2017, Clinical pharmacology in drug development.

Population pharmacokinetics (popPK) and exposure-response (ER) analyses to confirm alectinib 600 mg BID dose selection in a crizotinib-progressed or intolerant population.

K. Bogman, M. Martin-Facklam, P. N. Morcos, 2016 .

High prevalence of unknown co-medication in hospitalised patients

W. Haefeli, I. Walter‐Sack, M. Martin-Facklam, 2004, European Journal of Clinical Pharmacology.

Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans

Anil Kumar, Yun Zhou, Dean F. Wong, 2013, NeuroImage.

Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL.

Gerd Mikus, Walter E Haefeli, Meret Martin-Facklam, 2002, British journal of clinical pharmacology.

Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature

Walter E. Haefeli, Hermann Brenner, Meret Martin-Facklam, 2005, European Journal of Clinical Pharmacology.

Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities

Stephen Fowler, Meret Martin-Facklam, Michael Gertz, 2017, Current Pharmacology Reports.

Large-Scale Continuous Mobility Monitoring of Parkinson's Disease Patients Using Smartphones

Liping Jin, Detlef Wolf, Martin Koller, 2017, MobiHealth.

Highly sensitive determination of saquinavir in biological samples using liquid chromatography-tandem mass spectrometry.

W. Haefeli, G. Mikus, J. Burhenne, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management?

W. Haefeli, V. Bergk, M. Martin-Facklam, 2004, European Journal of Clinical Pharmacology.

Physiologically Based Absorption Modelling to Predict the Impact of Drug Properties on Pharmacokinetics of Bitopertin

N. Parrott, D. Hainzl, M. Martin-Facklam, 2014, The AAPS Journal.

[Individualization of drug therapy in renal or liver insufficiency].

M. Martin-Facklam, 2000, Therapeutische Umschau. Revue therapeutique.

Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers

A. Patat, F. Pizzagalli, L. Ereshefsky, 2016, Psychopharmacology.

Results from a phase 1b multiple ascending-dose study of PRX002/RG7935, an Anti-alpha-synuclein monoclonal antibody, in patients with Parkinson’s disease

J. Jankovic, D. Jennings, J. Quinn, 2018 .

Human Activity Recognition from Sensor-Based Large-Scale Continuous Monitoring of Parkinson’s Disease Patients

Liping Jin, Detlef Wolf, Martin Koller, 2017, 2017 IEEE/ACM International Conference on Connected Health: Applications, Systems and Engineering Technologies (CHASE).

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.

M. Ostland, D. Umbricht, G. Garibaldi, 2014, JAMA psychiatry.